glp-1 receptor agonists in idiopathic intracranial hypertension The effect of agonist on hypertension: a systematic review and meta-analysis The effect of glucagon-like peptide-1

We anticipate around seven actual launches in the US by 2030 after risk-adjustment

Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice

(2023) 46:S128S39

Following the massive success of WEGOVY (semaglutide 2.4 mg), the company is evaluating semaglutide 7.2 mg in phase III obesity drug clinical trials

The manufacturers of GLP1-RAs typically recommend lowering doses of insulin and insulin secretagogues at the initiation of GLP-1 RA treatment to reduce the risk of hypoglycemia

Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial